Asthma affects hundreds of millions of people, and many flare-ups are preventable. The treatments exist; the hard part is using them well, dose after dose, with technique that holds. That gap is where Respiro started.
Working with Reply and the University of Twente through the ACT4Y initiative, we built a digital prescription-intervention service: inhaler sensors and usage data paired with pulmonary-pharmacist support, to help patients stay on therapy and use it correctly.
The early evaluation pointed in one direction. Adherence improved, inhaler technique improved, and asthma-control scores rose. Commercial programmes that followed reported similar gains in adherence and technique, with less reliance on reliever medication.
Originally published 6 May 2019. These are early figures from specific study populations, reported at the time and being reconciled with our current evidence base; they are not a promise of individual results.